KMO and schizophrenia: Patients with schizophrenia display a significant reduction in KMO gene expression (Wonodi et al., 2011), and an increase in brain and cerebrospinal fluid (CSF) concentrations of the endogenous N‐methyl‐d‐aspartate receptor antagonist.